Arca
Skip to content
Tools
Tools

-mig

A bispecific or multispecific antibody: one molecule built to bind two or more different targets. Part of the 2021 scheme.

  • Drugs ending in -mig: 63
  • Approved somewhere: 0
  • With a US drug page: 0

What it means

Stem from WHO's stem book, 2024; description by Arca
Stem
-mig
Class
Bispecific and multispecific antibodies (2021 naming scheme)
Most common targets
PDCD1 (1), HAVCR2 (1)

Drugs that carry it

Approved and clinical-stage drugs in ChEMBL whose names ending in -mig, matched by spelling; those with a US drug page link to it.
Acts on
EtentamigPhase 3——
RilvegostomigPhase 3——
VolrustomigPhase 3——
AcimtamigPhase 2——
AmostomigPhase 2——
AzerutamigPhase 2——
BexatamigPhase 2——
BrivekimigPhase 2——
CabotamigPhase 2——
CiduvectamigPhase 2——
CizutamigPhase 2——
ClesitamigPhase 2——
CugrastomigPhase 2——
DalmitamigPhase 2——
DanvilostomigPhase 2——
DonzakimigPhase 2——
FanastomigPhase 2——
ForimtamigPhase 2——
GalvokimigPhase 2——
GivastomigPhase 2——
GocatamigPhase 2——
ItanistomigPhase 2——
LinclatamigPhase 2——
LofacimigPhase 2——
LomvastomigPhase 2PDCD1, HAVCR2Programmed cell death protein 1 inhibitor
LunsekimigPhase 2——
MipletamigPhase 2——
NebratamigPhase 2——
ObertamigPhase 2——
ObrixtamigPhase 2——
OmpekimigPhase 2——
Opugotamig olatansinePhase 2——
PamvatamigPhase 2——
PasritamigPhase 2——
PeluntamigPhase 2——
PodentamigPhase 2——
RagistomigPhase 2——
RezetamigPhase 2——
SabestomigPhase 2——
SafimestomigPhase 2——
SilevimigPhase 2——
SpevatamigPhase 2——
SurovatamigPhase 2——
TarperprumigPhase 2——
TilatamigPhase 2——
Tilatamig samrotecanPhase 2——
TilrekimigPhase 2——
TobemstomigPhase 2——
TovecimigPhase 2——
TrevotamigPhase 2——
UmizortamigPhase 2——
VelinotamigPhase 2——
VonsetamigPhase 2——
XirestomigPhase 2——
ZeripatamigPhase 2——
ZubotamigPhase 2——
AvitotamigPhase 1——
DavutamigPhase 1——
DenecimigPhase 1——
EnristomigPhase 1——
IngitamigPhase 1——
NezastomigPhase 1——
ZifibancimigPhase 1——

Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.